NCT02249871已完成1 期
A Trial Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Area under the semaglutide plasma concentration time curve
研究概览
简要总结
This trial is conducted in Europe. The aim of this trial is to investigate the influence of omeprazole on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female age 18-75 years (both inclusive) at time of signing informed consent
- •Body mass index of 18.5-29.9 kg/m^2 (both inclusive)
- •A good general health based on medical history, physical examination, and results of vital signs, electrocardiogram and laboratory safety tests performed during the screening visit, as judged by the investigator
排除标准
- •Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods. Female of child bearing potential must use effective methods of birth control for the duration of the trial and for 5 weeks following last dose. Only highly effective methods of birth control are accepted (i.e., one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices)
- •History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease
- •Hypertension (defined as sitting systolic blood pressure above or equal to 140 mmHg and/or diastolic blood pressure above or equal to 90 mmHg). If white-coat hypertension is suspected at the screening visit a repeated measurement is allowed
- •Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening
研究组 & 干预措施
Semaglutide
Experimental
干预措施: semaglutide (Drug)
Semaglutide + Omeprazole
Experimental
干预措施: semaglutide (Drug)
Semaglutide + Omeprazole
Experimental
干预措施: Omeprazole (Drug)
结局指标
主要结局
Area under the semaglutide plasma concentration time curve
时间窗: From time 0 to 24 hours after the 10th daily dose
次要结局
- Area under the SNAC plasma concentration time curve(From time 0 to 24 hours after the 10th daily dose)
- Number of hypoglycaemic episodes(From first dosing (Day 1) to completion of the follow-up visit (Day 43 (± 2 days)))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy VolunteersHealthy VolunteersNCT05497557Amgen16
招募中
不适用
A study to evaluate the benefit of omeprazole in the prevention of bleeding from esophageal ulcer after esophageal varicesPatients with esophageal ulcer (no less than 20 years old)JPRN-UMIN000005749Gifu University30
已完成
1 期
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy SubjectsHealthyDiabetesNCT01931137Novo Nordisk A/S45
已完成
1 期
A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT01618188Novo Nordisk A/S52
已完成
1 期
A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT01590836Novo Nordisk A/S22